ArticleScientific reports2025
Clinical significance of level VII lymph node metastasis in papillary thyroid cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and internal validation of a multivariable MRI-based radiomics prediction model for preoperative cervical lymph node metastasis in thyroid cancer.Gland surgery · 2026Article
- CENPM as a biomarker and therapeutic target for lymph node metastasis in thyroid carcinoma.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The reclassification of level VII lymph node metastasis (LNM) from N1b to N1a in papillary thyroid carcinoma (PTC) has sparked debate due to limited evidence on its prognostic impact. This study aims to investigate the impact of level VII LNM on cancer-special survival (CSS) in PTC patients. We analyzed data from 40,371 PTC patients in the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015. The effect of different nodal groups (N0, N1a, N1b and VII) on CSS was evaluated using hazard ratios (HRs) and absolute survival or death probability differences. Cox and Fine-Gray models were employed to estimate HRs with 95% confidence intervals (CIs). Logistic regression analysis was utilized to identify risk factors for level VII LNM. Level VII metastasis was present in 2.0% (817/40,371) of PTC patients. These patients exhibited more aggressive clinicopathological features and received more intensive treatments compared to other nodal groups. Multivariate Cox analysis revealed that level VII LNM was associated with the poorest CSS (adjusted HR for VII vs. N0: 5.67). The adjusted 10-year survival difference between the N0 and VII groups was 2.97%. Independent risk factors for level VII LNM included young age, male gender, white race, large tumor size, extrathyroidal extension and multifocality. Level VII LNM in PTC represents a distinct entity with aggressive clinical behavior and poor prognosis, which suggests the need for tailored clinical management strategies and potential revision of the current N staging system for PTC patients with level VII LNM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.